{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:16:01Z","timestamp":1767867361994,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1097\/00019442-200409000-00005","type":"journal-article","created":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T10:21:32Z","timestamp":1232533292000},"page":"473-482","source":"Crossref","is-referenced-by-count":31,"title":["Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Constantine G.","family":"Lyketsos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Reichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kershaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/00019442-200409000-00005_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1097\/00019442-200409000-00005_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1097\/00019442-200409000-00005_bib3","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1097\/00019442-200409000-00005_bib4","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1097\/00019442-200409000-00005_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease: results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1097\/00019442-200409000-00005_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archneur.56.11.1388","article-title":"The spectrum of behavioral responses to cholinesterase-inhibitor therapy in Alzheimer disease","volume":"56","author":"Mega","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1097\/00019442-200409000-00005_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"10.1097\/00019442-200409000-00005_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)08675-4","article-title":"Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically-acting ligands","volume":"49","author":"Schrattenholz","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1097\/00019442-200409000-00005_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0022-3565(24)36503-6","article-title":"Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function","volume":"280","author":"Albuquerque","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/00019442-200409000-00005_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF02247426","article-title":"Effects of acute subcutaneous nicotine on attention, information-processing, and short-term memory in Alzheimer's disease","volume":"108","author":"Jones","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1097\/00019442-200409000-00005_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002130050667","article-title":"Nicotinic acetylcholine involvement in cognitive function in animals","volume":"138","author":"Levin","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1097\/00019442-200409000-00005_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0079-6123(08)62495-4","article-title":"The role of nicotinic receptors in the pathophysiology of Alzheimer's disease","volume":"79","author":"Nordberg","year":"1989","journal-title":"Prog Brain Res"},{"key":"10.1097\/00019442-200409000-00005_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1097\/00019442-200409000-00005_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-Mental State\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"suppl 1","key":"10.1097\/00019442-200409000-00005_bib15","first-page":"S7","article-title":"Measuring response to treatment in Alzheimer's disease: what constitutes meaningful change?","volume":"1","author":"Mohs","year":"1998","journal-title":"Int J Geriatr Psychopharmacol"},{"key":"10.1097\/00019442-200409000-00005_bib16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1097\/00019442-200409000-00005_bib17","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1097\/00019442-200409000-00005_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(01)05623-9","article-title":"Effect of hydroxylchloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study","volume":"358","author":"Van Gool","year":"2001","journal-title":"Lancet"},{"key":"10.1097\/00019442-200409000-00005_bib19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease","volume":"336","author":"Sano","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1097\/00019442-200409000-00005_bib20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1176\/ajp.151.3.390","article-title":"A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration","volume":"151","author":"Stern","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1097\/00019442-200409000-00005_bib21","first-page":"1","article-title":"Clinical trials in dementia: learning effects with repeated testing","volume":"16","author":"Claus","year":"1991","journal-title":"J Psychiatry Neurosci"},{"key":"10.1097\/00019442-200409000-00005_bib22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1212\/WNL.43.8.1559","article-title":"Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease","volume":"43","author":"Galasko","year":"1993","journal-title":"Neurology"},{"key":"10.1097\/00019442-200409000-00005_bib23","unstructured":"Davis BM, Mohs RC: Learning effects on the ADAS-Cog explain much of the apparent difference between donepezil and rivastigmine. Poster presented at: American College of Neuropsychopharmacology; December 9, 2002; San Juan, Puerto Rico"},{"key":"10.1097\/00019442-200409000-00005_bib24","doi-asserted-by":"crossref","unstructured":"Torfs K, Feldman H:12\u2013month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease treated with placebo in two randomized studies. Poster presented at: 7th International World Alzheimer Congress; July 9\u201318, 2000, Washington, DC","DOI":"10.1016\/S0197-4580(00)83429-6"},{"key":"10.1097\/00019442-200409000-00005_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000106650","article-title":"A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R: The European Propentofylline Study Group","volume":"8","author":"Marcusson","year":"1997","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1097\/00019442-200409000-00005_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1097\/00019442-200409000-00005_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.1097\/00019442-200409000-00005_bib28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748112612196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748112612196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T02:54:10Z","timestamp":1738896850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748112612196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":28,"aliases":["10.1176\/appi.ajgp.12.5.473"],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S1064748112612196"],"URL":"https:\/\/doi.org\/10.1097\/00019442-200409000-00005","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}